L'activité du Docteur PIRENNE, se répartit sur 3 sites:
Consultation privée:
Centre de Cardiologie Charlemagne à Louvain-La-Neuve
Activité hospitalière:
Clinique St Pierre (Service de Cardiologie)
Consultation Polyclinique:
Centre Médical de Wavre (CSPO)
L'activité du Docteur PIRENNE, se répartit sur 3 sites:
Consultation privée:
Centre de Cardiologie Charlemagne à Louvain-La-Neuve
Activité hospitalière:
Clinique St Pierre (Service de Cardiologie)
Consultation Polyclinique:
Centre Médical de Wavre (CSPO)
​
CURRICULUM VITAE du Docteur Bruno Pirenne
Date de naissance Ixelles, 19 septembre 1957
Nationalité Belge
Situation familiale : Trois enfants (1990, 1991, 1995).
Adresse professionnelle Clinique St Pierre - Service de Cardiologie
Avenue Reine Fabiola, 1340 Ottignies
Téléphone 010/43.73.47 (secrétariat).
010/43.71.90 (direct)
Fax 010/437.139
Adresse professionnelle Centre de Cardiologie Charlemagne
Avenue de l’Union Européenne, 16
1348 Louvain La neuve
Téléphone 010/23.87.11
E mail dr.pirenne@cardiolln.be
Sports/ Loisirs : Natation, randonnées, photo, musique.
Enseignement et Formations :
Enseignement universitaire et postuniversitaire:
1975 - 1982 Université Catholique de Louvain
Faculté de Médecine de Louvain-en-Woluwe, 1200 Bruxelles.
Spécialisation en Cardiologie : UCL
1982 - 1983 Clinique Sainte-Elisabeth, Namur,
service de Médecine Interne (Dr. A Cuvelier),
1983 - 1984 Centre Hospitalier de Luxembourg, Luxembourg
service de Médecine Interne (Dr. M. Dicato
1984 - 1985 Clinique Saint-Michel, Bruxelles,
service de Médecine Interne (Dr. P. Dewil),
1985 - 1986 Clinique Saint-Jean, Bruxelles,
service de Cardiologie (Dr. P. Gruwez),
1986 – 1987 Cliniques Universitaires de Mont-Godinne
service de Cardiologie (Prof. R. Kremer)
Cliniques Univeristiares Saint-Luc, Bruxelles
service de Cardiologie (Prof. L. Brasseur).
Spécialisation en Soins Intensifs : UCL
1987 - 1988 Hôpital Cantonal, Genève
Division des soins intensifs chirurgicaux, (Prof. P.M. Suter).
Division des soins intensifs médicaux, (Dr. J.C. Chevrolet)
1988 – 1989 Cliniques Universitaires St-Luc, Bruxelles
Département des Soins Intensifs,
Unité Cardiaque Médicale et Coronarienne (Prof. J. Col)
Unité de Chirurgie Cardio-thoracique (Prof. M. Goenen).
Formation en éthique biomédicale
1995-2000 Universite Catholique de Lille
Centre d’Ethique Médicale, D. Jacquemin.
Diplômes et agréation:
1982 Docteur en Médecine, Chirurgie et Accouchements, UCL,
1987 Spécialiste en Cardiologie, UCL
1989 Certificat de Médecine Intensive et d'Urgences, UCL
1987 Agréation INAMI en Cardiologie
1989 Agréation INAMI en Médecine Interne
1997 Compétence légale en Medecine Intensive, renouvellée en 2002, 2007
puis à titre définitif en 2012.
Expérience professionnelle :
1989-2009 : Service de Soins Intensifs
Clinique Saint-Pierre, 1340 Ottignies.
1990-2000 : Cliniques St Luc - 1200 Bruxelles
Cardiologie interventionnelle (1demi-jour /semaine).
1999-2005 : Médecin Chef de Service
Service de Soins Intensifs
Clinique St Pierre 1340 Ottignies.
2009 – ongoing Activité de gardes
2009 – ongoing : Service de Cardiologie
Clinique Saint Pierre
BHC ,
2013-2016 Coordinateur Médical
Brussels - Brabant Heart Center
Expérience en cardiologie :
Coronarographie, 1990-2008, CSPO
Cardiologie Interventionnelle, UCL, 1988-2000
Echographie cardiaque (transthoracique et transoesophagienne)
Scan coronaire, 2009
Recherche clinique 1993-ongoing
Ethique biomédicale :
Membre du Comité d’Ethique, clinique St Pierre, 2006
Président du Comité d’Ethique, clinique St Pierre, 2013- ongoing
Sociétés scientifiques :
Membre correspondant de la Société Belge de Médecine Intensive, avril 1992.
Membre ordinaire de la Société Européenne de Soins Intensifs, 1996.
Membre du Belgian interdisciplinary working group on acute cardiology (BIWAC), 1998
Membre de la Société Européenne de Cardiologie, 2012
Membre de la Société Européenne de Cardiologie, heart failure association, 2008Cliniques St Luc - 1200 Bruxelle
Travaux scientifiques
A-Publications
1.- Pirenne B, Marchandise B :
Electrocardiogramme et hypothermie : à propos d'un cas.
Arch. Mal. Coeur. 1988.81:1017-1020.
2.- Bohon Ph. Dugernier T, Debongnie JC, Pirenne B.
Pneumopathie interstitielle d'hypersensibilité et recto-colite ulcéro-hémorragique : rôle du methotrexate.
Acta Gastroente Bel 1993,56:352-7.
3.- Col J, Pirenne B, Decoster O, Payen B, Deligne B, Purnode P, Bachy JL, Renkin J.
Basic components and patterns of acute ischemia recovery assessed from continuous ST monitoring in acute
myocardial infarction treated by thrombolytic therapy.
Journal of Electrocardiology. 1994:27 supplement, 241-248.
4.- Amrani M, Rubay J, Pirenne B, Col J, Dion R.
Isolation of the left coronary artery ostium by an aortic cusp attachment : a rare cause of myocardial ischemia.
Eur J Cardio-thorac Surg, 1994 8:663-664.
5.- Renkin J, Pirenne B, Carlier M, Col J.
Traitement de l'infarctus du myocarde. Thrombolyse ou angioplastie ?
Louvain Médical 1995 114:223-6.
6.- Al Shwafi K, de Meester A, Pirenne B, Renkin J, Col J :
Rapid detection of streptokinase resistance using a bedside lytic assay of dry recipent technology.
Fibrinolysis and Proteolysis, 2000,14(6);1-7.
7;- Honoré PM, Jamez J, Wauthier M, Lee PA, Dugernier T,Pirenne B,Hanique G, Matson JR.
Prospective evaluation of short term, high volume isovolemic hemofiltration on the hemodynamic course
and outcome in patients with intractable circulatory failure from septic shock.
Crit Care Med 2000 Nov;28 (11): 3581-7. 12.-
8,- R. Colenbunders, J.L. Mariage,J.CH Coche, B. Pirenne, S. Kempinaire, Ph. Hantson, A. Van Gompel,
M. Niedrig, M. Van Esbroeck, R. Bailey, C. Drosten, and H. Scmitz:
A belgian traveler who acquired yellow fever in the gambia.
Clin; Infect; Dis. 2002, Nov 15;35 (10): e113-6. Epub 2002 Oct 28.
9,- Kamal A. Al Shawafi, Antoine de Meester, Bruno Pirenne, Jacques J. Col.
Comparative fibrinolytic activity of front-loaded alteplase and the single bolus mutants tenecteplase
and lanoteplase during treatment of acute myocardial infarction.
Am Heart J 2003; 145:217-25.
10. Double-Blind Parallel Placebo-Controlled Study to Evaluate the Effect of Molsidomine on the Endothelial Dysfunction
in Patients with Stable Angina Pectoris Undergoing Percutaneous Coronary Intervention: the MEDCOR Trial.
Barbato E, Herman A, Benit E, Janssens L, Lalmand J, Hoffer E, Chenu P, Guédès A, Missault L, Pirenne B,
Cardinal F, Vercauteren S, Wijns W.
J Cardiovasc Transl Res. 2013 Oct 19. [Epub ahead of print]
11. Barbato E, Herman A, Benit E, Janssens L, Lalmand J, Hoffer E, Chenu P, Guédès A, Missault L, Pirenne B,
Cardinal F, Vercauteren S, Wijns W.
Double-blind parallel placebo-controlled study to evaluate the effect of molsidomine on the endothelial dysfunction
in patients with stable angina pectoris undergoing percutaneous coronary intervention: the MEDCOR Trial.
J Cardiovasc Transl Res. 2014 Mar;7(2):226-31. doi: 10.1007/s12265-013-9513-9. Epub 2013 Oct 19.
​
B - Abstracts
1.- Pirenne B, Bruchner JC, Suter PM :
Intérêt de la mesure de la dépense énergétique en médecine intensive.
Assemblée Annuelle Suisse de Médecine Intensive. Montreux, 1988.
Schweiz. Med. Wschr 1989;119:384.
2.- Palazzo M, Pirenne B, Morel DR, Suter PM :
Relationship between O2 consumption and O2 delivery in severely ill patients with reference to their
hormonal status and outcome.
Assemblée Annuelle Suisse de Médecine Intensive. Montreux, 1988.
Schweiz. Med. Wschr 1989;119:380.
3.- Col J, Decoster O, Hanique G, Deligne B, Boland J, Pirenne B, Cheron P, Renkin J :
Infusion of heparin conjunct to streptokinase accelerates reperfusion of acute myocardial infarction :
results of double blind randomized stury (OSIRIS).
American Heart Association, New Orleans, novembre 1992. Circulation 86, I 259, 1992.
4.- Decoster O, Boland J, Pirenne B, Cheron P, Renkin J, Col J :
Recovery patterns obtained from continuous ST segment monitoring during thrombolysis for acute myocardial
infarction are good predictors for coronary recanalization. American College of Cardiology, Anaheim, Mars 1993.
JACC 21,459A, 1993.
5.- Decoster O, Renkin J, Boland J, Pirenne B, Cheron P, Col J.
Recovery patterns obtained from continuous ST segment monitoring during thrombolysis for acute myocardial
infarction are accurate Predictor for successful myocardial reperfusion.
European Society of Cardiology, Nice, Septembre 1993.
Eur. Heart J, 1993 14:354.
6.- Col J, Al Shwafi K, Pirenne B, Renkin J, Van de Werf F.
Analysis of continuous ST-segment monitoring as a surrogate to coronary angiograms for assessing
thrombolytic efficacy. Application in the GUSTO trial.
Annual scientific meeting of the Belgian Society of Cardiology, Brussels, February 1996.
Acta Cardiologica Belgica, 1996, 51(1), 44.
7.- Al Shwafi K, Col J, Pirenne B, de Meester A, Miesse C, Renkin J :
Lytic activity with accelerated t-PA assessed at bedside during thrombolytic therapy for acute myocardial infarction.
JACC, 1997,29(2), 1034-54,1997.
Thrombosis and hemostasis, 1997:suppl june:502.
8.- Col J, Al Shwafi K, Pirenne B, de Meester A, Miesse C, Renkin J.
Lytic activity profile of 1.5 MU streptokinase infused in 6O minutes for acute myocardial infarction.
European Society of Cardiology.
August 24-28, 1997. Stockholm - Sweden.
Eur. Heart Journal, 1997, 18(suppl.), 634.
9.- de Meester A, Al Shwafi K, Pirenne B, Miesse C, Renkin J, Col J.
Comparison of lytic activities during accelerated t-PA and streptokinase infusion in patients treated for acute
myocardial infarction.
European Society of Cardiology. August 24-28, 1997. Stockholm - Sweden.
Eur. Heart Journal. 1997,18(suppl.),634.
10.- Al Shwafi K, de Meester A, Pirenne B, Miesse C, Renkin J, Col J.
Comparative lytic activity profiles of accelerated infusion of t-PA and 30 mgr bolus of TNK-tPA.
European Society of Cardiology. August 24-28, 1997. Stockholm - Sweden.
Eur. Heart Journal, 1997, 18(suppl), 633.
​
11.- Al Shwafi K, de Meester A, Pirenne B, Renkin J, Col J.
Rapid establishment of intense lytic activity with t-PA correlates with early ST elevation resolution as
predictor of outcome after AMI.
Circulation, 1997 : 96,8(supplément):260.
12.- Vranckx P, Al Shwafi K, de Meester A, Pirenne B, Jacquet L, Renkin J, Col J.
In vitro lytic response to 1OO U/ml streptokinase predicts ECG response to standard dose of streptokinase for AMI.
Circulation, 1997 : 96,I 260:1445.
13.- de Meester A; Al Shwafi K, Pirenne B, Vranckx P, Renkin J et Col J.
In-vitro streptokinase resistance test for rapid prediction of coronary artery patency using continuous
ST-segment monitoring during acute myocardial infarction.
Acta Cardiologica Vol LII, 1997:6:556-557.
14.- de Meester A; Al Shwafi K, Pirenne B, Vranckx P, Renkin J et Col J.
The thrombolytic response early during the 60-minutes infusion of 1.5 MU streptokinase determined the extent of
ST segment resolution in patients with acute myocardial infarction.
Acta Cardiologica Vol LII,1997:6:543-544.
15.- Al Shwafi K, de Meester A, Pirenne B, Vranckx P, Renkin J, Col J.
Rapid clot lysis test predicts lytic response to streptokinase therapy for acute myocardial infarction.
European Society of Cardiology, August, 22-26, 1998, Vienna.
Eur Heart J, 1998,19:280.
J Am Coll Cardiol 1998:31, suppl C:454.
16.- Al Shwafi K, de Meester A, Pirenne B et al. Rapid clot lysis test predicts lytic response to streptokinase therapy
for acute myocardial infarction.
J Am Coll Cardiol 1998:31:454.
17.- Al Shwafi K, de Meester A, Pirenne B, Renkin J, Col J.
Bedside lytic activity assessment during accelerated tPA and TNK-tPA therapy for acute myocardial infarction.
J Am Coll Cardiol 1998;31:452A.
18.- de Meester A, Al Shwafi K, Pirenne B et al.
In vitro streptokinase test for rapid prediction of coronary artery patency by angiography after acute
myocardial infarction.
Eur Heart J 1999.
19.- Al Shafi K, de Meester A, Pirenne B, Vranckx P, Renkin J, Col J.
Evaluation of a rapid bedside test for streptokinase resistance applied in acute myocardial infarction (abstract).
Eur Heart J 1999;20(suppl):516.
20. Emanuele Barbato, Arnold Herman , Edouard Benit , Luc Janssens , Jacques Lalmand , Etienne Hoffer
Patrick Chenu , Antoine Guedes , Luc Missault ,Bruno Pirenne , François Cardinal, Steven Vercauteren , William Wijns .
Long-term effect of molsidomine, a direct nitric oxide donor, as an add-on treatment, on endothelial dysfunction
in patients with stable angina pectoris undergoing percutaneous coronary intervention: Results of the MEDCOR trial.
Atherosclerosis 240 (2015) 351e354
C - Présentations
1.- Cosyns J, Pirenne B, Vanoverschelde JL, Rousseau M, Wyns W, Raphael D :
Validity of Echo-Doppler assessment of aortic stenosis.
Its impact on decision making between surgery and valvuloplasty.
First Belgian Meeting on Echocardiography and Cardiac Doppler. Bruxelles, 1987.
2.- Pirenne B, Vanoverschelde JL, Col J :
Le devenir du coeur greffé et les méthodes d'évaluation de sa fonction.
"La transplantation cardiaque à l'UCL, 1985-1990.
Réunion trimestrielle de Cardiologie, 9 mars 1990.
3.- Decoster O, Boland J, Cheron P, Pirenne B, Renkin J, Col J.
Continuous ST segment monitoring during thrombolysis for acute myocardial infarction predicts
accurately coronary recanalization.
Seventh Annual Meeting of the BWGIC, Bruxelles, 1992.
4.- Pirenne B, Col J :
Monitoring du segment ST : intérêt et applications cliniques.
Journées d'enseignement pour Paramédicaux.
Sodehotel, Bruxelles, avril 1993.
5. Col J, Pirenne B, Decoster O, Payen B, Deligne B, Purnode P, Bachy JL, Renkin J.
Basic components and patterns of acute ischemia recovery assessed from continuous ST monitoring
in acute myocardial infarction treated by thrombolytic therapy.
International Society for Computerized Electrocardiology, Santa Barbara, U.S.A. April 28th.
6.- Pirenne B :
Monitoring ST et pathologie coronarienne aigue.
Journée d'enseignement pour paramédicaux, Charleroi, novembre 1994.
7.- Jamez J, Wauthier M, Dugernier Th, Honore P, Pirenne B, Moos B, Hassoun A.
Haemodialysis : A new and possible alternative therapeutic approach in acute intermittent porphyria crises.
International association for the study of the liver. February 1996. Cape Town, South Africa.
8.- Al Swhafi K, Col J, Pirenne B, de Meester A, Miesse C, Renkin J.
Lytic activity with accelerated t-PA assessed at bedside during thrombolytic therapy for acute myocardial infarction.
Annual scientific meeting of the Belgian Society of Cardiology, Brussels, January 1997.
9.- Pirenne B.
Les syndromes coronariens aigus:
Cycle de formation complémentaire spécialisée en soins intensifs,
CPSI, ACN, Bruxelles, 1996-1997
10.- Pirenne B :
Thrombolyse et angioplastie coronaire,
Cycle de formation complémentaire spécialisée en soins intensifs,
CPSI, ACN, Bruxelles 1996-1997.
11.- Pirenne B:
Pathologie coronarienne aiguë: de la physiopathologie au traitement,
Cycle de spécialisation en soins intensifs,
CPSI, ACN, Bruxelles, 1996-1997.
12.- Al Shwafi K, de Meester A, Pirenne B, Miesse Ch, Vranckx P, Renkin J, Col J.
Clinical value of a new method of thrombolytic assessment.
Société Belge de Médecine Intensive et de Médecine d'Urgence. May 1998.
13.- Al Shwafi K, de Meester A, Pirenne B, Vranckx P, Renkin J, Col J.
Rapid clot lysis test predicts lytic response to streptokinase therapy for acute myocardial infarction.
Société Belge de Cardiologie, 5-6-7 February 1998, Brussels.
14.- de Meester A, Al Shwafi K, Pirenne B, Vranckx P, Renkin J, Col J.
The thrombolytic response early during the 60-minutes infusion of 1,5 MU streptokinase determined
the extent of ST segment resolution in patients with acute myocardial infarction.
Société Belge de Cardiologie, 5-6-7 February 1998, Brussels.
15.- Pirenne B :
Les progrès du scan coronaire dans la détection de la maladie coronaire.
Symposium de cardiologie, BHC, Genval, 2010
16. - Pirenne B. :
Nouveautés en imagerie médicale dans les secteur cardiovasculaire. Apport du scan coronaire.
Symposium de soins infirmiers dans le secteur cardiovasculaire, Leuven may 2012
​
Participation aux études cliniques : 1993-2016
1.- GUSTO I :
Global utilization of streptokinase ant t-PA for occluded arteries I.
NEJM 1993,329:673-82.
​
2.- GUSTO II :
Global use of strategies to open occluded coronary arteries II.
Circulation 1994;90:1631-7.
NEJM 1996;335/775-82.
​
3.- OPUS-TIMI 16 :
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
AHA, novembre 1999.
Circulation. 2000 Jul 11;102(2):149-56.
​
4.- IN TIME II :
Intravenous nPA for treatment of infarcting myocardium early.
Eur Heart J, 2000;21:2005-2013.
​
5.- ASSENT 2 TRIAL
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction:
The ASSENT-2 double-blind randomised trial.
Lancet. 1999 Aug 28;354(9180):716-22.
6.- EXTRACT–TIMI 25
Enoxaparin andThrombolysis Reperfusion for AcuteMyocardial Infarction Treatment
Thrombolysis in Myocardial Infarction 25.
NEJM,2006, 1-12
​
7. OAT trial:
Coronary intervention for persistent occlusion after myocardial infarction
N Engl J Med. 2006 Dec 7;355(23):2395-407. Epub 2006 Nov 14.
​
8.- MERLIN-TIMI 36
Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non–ST-Elevation acute coronary syndromes
JAMA. 2007;297(16):1775-1783
​
9.- IMPROVE-IT trial : investigateur principal
A multicenter, double blind, randomized study to establish the clinical benefit and safety of Vytorin
(Ezetimibe/simvastatin tablet) vs Simvastatin monotherapy in high risk subjects presenting
with acute coronary syndrome.
ongoing
Schering-Plough 2009
​
10.- PEGASUS TIMI 54 trial: investigateur principal
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial,
to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background
of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of Myocardial Infarction
Ongoing
Astra-Zeneca 2011-2013
​
11. EPICOR :
Registre syndromes coronariens aigus.
Astra Zeneca 2010-2011
​
12. trial:
A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of
LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and
reduced ejection fraction
Novartis 2010
​
13. CANTOS trial: investigateur principal
A randomized, double-blind, placebo-controlled, event driven trial of quarterly subcutaneous
canakinumab in theprevention of recurrent cardiovascular events amongstable post-myocardial infarction
patients with elevated hsCRP
Ongoing, 2012
ovartis 2012.
​
14. MEDCOR trial:
Double-blind parallel placebo-controlled study to evaluate the effect of Molsidomine on the
Endothelial Dysfunction in patients with stable angina pectoris undergoing a percutaneous CORonary intervention.
Ongoing, 2012
Therabel Pharma 2012
​
15. ODYSSEY trial, investigateur principal
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the
effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients who have Recently
Experienced an Acute Coronary Syndrome.
Ongoing 2013-2015
Sanofi
​
16. Ivabradine in HF-PEF, investigateur principal
Effects of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation,
in patients with Chronic Heart Failure and Preserved left ventricular Ejection Fraction
2013
Servier
​
17. Paragon: investigateur principal
A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and
safety of LCZ696 compared to valsartan on morbidity and mortality in patients with Chronic heart failure and
preserved ejection fraction
Ongoing , 2015
Novartis